Condition 1: Gestational trophoblastic disease. Condition 2: Choriocarcinoma. Gestational trophoblastic disease Chorioadenoma destruens
Conditions
Interventions
Intervention 1: EMA – CE =etoposide 100?mg/m2, methotrexate 300?mg/m2 and actinomycin D 0.5?mg on day 1 and 2 and Cisplatin 600?mg/m2, andetoposide 100?mg/m2 on days 8, were administered intravenously
Treatment - Drugs
EMA – CE =etoposide 100?mg/m2, methotrexate 300?mg/m2 and actinomycin D 0.5?mg on day 1 and 2 and Cisplatin 600?mg/m2, andetoposide 100?mg/m2 on days 8, were administered intravenously every 3 weeks
EMA – CO= etoposide 100?mg/m2, methotrexate 300?mg/m2 and actinomycin D 0.5?mg on day 1 and 2 and cyclophosphamide 600?mg/m2, and vincristine 1?mg/m2 (maximum dose of 2?mg) on days 8, were administere
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: all Pregnant Patients which did not respond enough to one-drug therapy; Mole Stage 1 or 2 , or Mole Score more than 7; no disorder in liver, renal or genital biochemical tests; no other neoplasmic disorder and willing to enter the study. Exclusion criteria: any signs of Renal or Liver Failure during the study; willing to go out of the study at any stage.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Beta-HCG levels. Timepoint: 12 hours after last chemotherapy dose. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSoheila Aminimoghaddam
Tehran University of Medical Sciences
Outcome results
None listed